Experimental protein therapy tested for Hard-to-Treat inflammation

NCT ID NCT06877364

Summary

This study tested an experimental protein therapy called GcMAF in adults with chronic inflammatory diseases like rheumatoid arthritis or chronic cystitis that didn't respond well to standard treatments. The two-part trial first checked the safety of different doses, then compared GcMAF against a placebo to see if it reduced inflammation and improved symptoms. The goal was to see if this new approach could help control these ongoing conditions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Center For New Medical Technologies

    Novosibirsk, Russia

Conditions

Explore the condition pages connected to this study.